Faster answers. Relieved parents.

The results pediatricians need now with syndromic infectious disease testing from BioFire.

It takes more than an exam to determine what’s causing alarming symptoms in a febrile child.

The BioFire^® FilmArray^® Panels utilize a syndromic approach—simultaneously testing for different pathogens that can cause similar symptoms—to deliver actionable results in about an hour. Create confidence in treatment plans for children and relieve anxious parents with faster answers from the BioFire^® FilmArray^® Respiratory 2 plus (RP2plus), BioFire^® FilmArray^® Meningitis/Encephalitis (ME) Panel, and BioFire^® FilmArray^® Gastrointestinal (GI) Panel. 

The BioFire ME Panel has been shown to:

• Improve treatment decisions by potential avoidance of unnecessary acyclovir use in HSV-negative pediatric patients.¹
• Reduce time-to-result by 10 hours compared to batch method.¹
• Reduce hospital stays by avoiding unnecessary hospital admissions by 30%.²
• Double the rate of pathogen detection compared to send-outs.²
• Reduce length of stay by 2 days in children with pediatric central nervous system infections.³

The BioFire RP2.1plus Panel has been shown to:

• Improve patient treatment decisions through avoidance of antibiotics in 30% of pediatric patients tested.⁴
• Provide results to pediatric patients while in the ED 38% more often.⁵
• Reduce hospital stays by 5 days for febrile infants with a positive result (compared to a negative result).⁶
• Identify pathogens more often: the BioFire^® FilmArray^® Respiratory 2 plus (RP2plus) Panel produced a 42% positive identification rate in a pediatric population.⁷

References:

1. Messacar K, Breazeale G, Robinson CC, Dominguez SR. Potential Clinical Impact of the FilmArray Meningitis/Encephalitis Panel in Children with Suspected Central Nervous System Infections. Diagn Microbiol Infect Dis. 2016 Sep;86(1):118-20.

2. McNabb K, Briggs K, McKinnet C. Implementation of a Rapid Molecular Meningitis Panel. 2017. Presented at Carolinas Health Quality Summit. 

3. O’Brien MP. et al, Impact of Cerebrospinal Fluid Multiplex Assay on Diagnosis and Outcomes of Central Nervous System Infections in Children: A before and after cohort study. Pediatr Infect Dis J. 2018 Sep; 37 (9) 868-871.1

4. Sutton C, Walton P, Williams M, Bastian T, Spires S. Impact of Multiplex Polymerase Chain Reaction Testing for Respiratory Pathogen Detection in Pediatric Patients. ID Week 2017, Poster 1607.

5. Rogers BB, Shankar P, Jerris RC, Kotzbauer D, Anderson EJ, Watson JR, O'Brien LA, Uwindatwa F, McNamara K, Bost JE. Impact of a rapid respiratory panel test on patient outcomes. Arch Pathol Lab Med. 2015 May;139(5):636-41.

6. McFall C, Salimnia H, Lephart P, Thomas R, McGrath E. Impact of Early Multiplex FilmArray Respiratory Pathogen Panel (RPP) Assay on Hospital Length of Stay in Pediatric Patients Younger Than 3 Months Admitted for Fever or Sepsis Workup. Clin Pediatr (Phila). 2018 Sep;57(10):1224-1226.

7. Subramony A, Zachariah P, Krones A, Whittier S, Salman L. Impact of Multiplex Polymerase Chain Reaction Testing for Respiratory Pathogens on Healthcare Resource Utilization for Pediatric Inpatients. J Pediatr. 2016 Jun;173:196-201.e2

8. Stockmann C et al. How well does physician selection of microbiologic tests identify Clostridium difficile and other pathogens in paediatric diarrhoea? Insights using multiplex PCR-baseddetection. Clin Microbiol Infect. 2015 Feb;21(2):179. 

9. Calderaro A et al. Contribution of the FilmArray® Gastrointestinal Panel in the laboratory diagnosis of gastroenteritis in a cohort of children: a two-year prospective study. Int J Med Microbiol. 2018 Jul;308(5):514-521.  

10. Pouletty M et al. Multiplex PCR reveals a high prevalence of multiple pathogens in traveller's diarrhoea in children. Arch Dis Child. 2019 Feb;104(2):141-146.  

11. Keske Ş et al. Rapid Molecular Detection of Gastrointestinal Pathogens and Its Role in Antimicrobial Stewardship. J Clin Microbiol. 2018 Apr 25;56(5). 

12. Beal SG et al. Gastrointestinal PCR Panel Improves Clinical Management and Lowers Health Care Costs. J Clin Microbiol. 2017 Dec 26;56(1). 

The BioFire GI Panel has been shown to:

• Help define the right treatment for the pediatric patients.^8,9,12
• Optimize antibiotic treatment in 27% of pediatric patients suffering from travelers diarrhea.¹⁰
• Decrease inappropriate antibiotic prescription from 41% to 20% when coupled with an antimicrobial stewardship program.¹¹
• Decrease the number of additional stool tests and imaging studies per patient.^8,12
• Decrease the inpatients discharge rate without stool test result from 34.1% to 5.4%.¹²

The BioFire^® FilmArray^® Panels utilize a syndromic approach—simultaneously testing for different pathogens that can cause similar symptoms—to deliver actionable results in about an hour. Create confidence in treatment plans for children and relieve anxious parents with faster answers from the BioFire^® Respiratory 2.1 plus (RP2.1plus) Panel, BioFire® FilmArray^® Meningitis/Encephalitis (ME) Panel, and BioFire^® FilmArray^® Gastrointestinal (GI) Panel.

If you could like more information please fill out and submit the form below:

"The BioFire ME Panel is a rapid test that will give you better quality of care, less stress for children, for families, for doctors."­

– Athanasios Michos, Associate Professor of Pediatrics and Infectious Diseases, Aghia Sophia Children's Hospital, University of Athens, Greece 

“Particularly with children that have a gastrointestinal infection, time is really an important factor. As soon as you can start … treatment, as soon as you can start fluid supplementation, the recovery of the child will be significantly faster and better.” 

– Prof. Dr. Stephan Gehring, Children’s Hospital, Johannes Gutenberg University, Mainz, Germany

Product availability varies by country. Consult your bioMérieux representative.